

34. Higgins LS, Go RS, Dingli D, et al. Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. *Clin Lymphoma Myeloma Leuk* 2016; 16: 447–452.
35. Hilal T, DiCaudo DJ, Connolly SM et al. Necrobiotic xanthogranuloma: a 30-year single-center experience. *Ann Hematol* 2018; 97: 1471–1479.
36. Sagiv O, Thakar SD, Morrell G, et al. Rituximab Monotherapy Is Effective in Treating Orbital Necrobiotic Xanthogranuloma. *Ophthalmic Plast Reconstr Surg* 2018; 34: e24–e27.
37. Jacobsen E, Shanmugam V, Jagannathan J. Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib. *N Engl J Med* 2017; 377: 2398–2399.
38. Matter MS, Bihl M, Juskevicius D. Is Rosai-Dorfman disease a reactive process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease. *Virchows Arch* 2017; 471: 545–547.
39. Hasegawa M, Sakai F, Okabayashi A, et al. Rosai-Dorfman Disease of the Lung Overlapping with IgG4-related Disease: The Difficulty in Its Differential Diagnosis. *Intern Med* 2017; 56: 937–941.
40. Ghawes MS, Ng T, Chen LYC. Confirmed Efficacy of Lenalidomide and Dexamethasone in Unresectable Cutaneous Facial Rosai-Dorfman-Destombes Disease *Mayo Clin Proc Innov Qual Outcomes* 2019; 3: 94–96.
41. Geller S, Busam K, Hamlin PA et al. Treatment of Rosai-Dorfman disease with oral bexarotene: a case series. *J Dermatolog Treat* 2018; doi: 10.1080/09546634.2018.1528001.
42. Averitt AW, Heym K, Akers L, et al. Sinus Histiocytosis With Massive Lymphadenopathy (Rosai Dorfman Disease): Diagnostic and Treatment Modalities for this Rare Entity Revisited. *J Pediatr Hematol Oncol* 2018; 40: e198–e202.
43. Huhn D. Therapy of malignant histiocytosis. *Haematol Blood Transfus* 1981; 27: 211–216.
44. Kommalapati A, Tella SH, Durkin M, et al. Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. *Blood* 2018; 131: 265–268.
45. Kommalapati A, Tella SH, Durkin M, et al. Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. *Blood* 2018; 131: 265–268.
46. Broadwater DR, Conant JL, Czuchlewski DR, et al. Clinicopathologic Features and Clinical Outcome Differences in De Novo Versus Secondary Histiocytic Sarcomas: A Multi-institutional Experience and Review of the Literature. *Clin Lymphoma Myeloma Leuk* 2018; 18: e427–e435.
47. Voruz S, Cairoli A, Naveiras O, et al. Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma. *Haematologica* 2018; 103: e39–e41.
48. Iwabuchi H, Kawashima H, Umezu H, et al. Successful treatment of histiocytic sarcoma with cladribine and high-dose cytosine arabinoside in a child. *Int J Hematol* 2017; 106: 299–303.
49. Gounder MM, Solit DB, Tap WD. Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation. *N Engl J Med* 2018; 378: 1945–1947.
50. Chen T, Gopal P. Follicular Dendritic Cell Sarcoma. *Arch Pathol Lab Med* 2017; 141: 596–599.
51. Facchetti F, Lorenzi L. Follicular dendritic cells and related sarcoma. *Semin Diagn Pathol* 2016; 33: 262–276.
52. Jain P, Milgrom SA, Patel KP, et al. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. *Br J Haematol* 2017; 178: 403–412.
53. Sasaki M, Izumi H, Yokoyama T, et al. Follicular dendritic cell sarcoma treated with a variety of chemotherapy. *Hematol Oncol* 2017; 35: 905–908.
54. Purkait S, Mallick S, Joshi PP, et al. Retroperitoneal and mediastinal follicular dendritic cell sarcoma: report of 3 cases with review of literature. *Hematol Oncol* 2017; 35: 374–379.
55. Ninkovic S, Cole-Sinclair MF. Interdigitating dendritic cell sarcoma: diagnostic pitfalls, treatment challenges and role of transdifferentiation in pathogenesis. *Pathology* 2017; 49: 643–646.
56. Nguyen CM, Cassarino D. Primary Cutaneous Interdigitating Dendritic Cell Sarcoma: A Case Report and Review of the Literature. *Am J Dermatopathol* 2016; 38: 628–631.
57. Di Liso E, Pennelli N, Lodovichi G, et al. Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature. *Cancer Biol Ther* 2015; 16: 1128–1135.
58. Minoia F, Bovis F, Davi S, et al. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. *J Pediatr* 2017; 189: 72–78.e3.
59. Lerkvaleekul B, Vilaiyuk S. Macrophage activation syndrome: early diagnosis is key. *Open Access Rheumatol* 2018; 10: 117–128.
60. Otrock ZK, Daver N, Kantarjian HM, et al. Diagnostic Challenges of Hemophagocytic Lymphohistiocytosis. *Clin Lymphoma Myeloma Leuk* 2017; 17: S105–S110.
61. Henter JL, Horne A, Aricó M et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer* 2007; 48: 124–131.
62. Šrámek J, Karvunidis T, Lysák D, et al. Hemofagocytární lymfohistiocytóza u dospělých - review a kazuistika. *Vnitř Lék* 2018; 64: 300–307
63. La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. *Blood* 2019; doi: 10.1182/blood.2018894618.
64. Bergsten E, Horne A, Aricó M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. *Blood* 2017; 130: 2728–2738.
65. Risma KA, Marsh RA. Hemophagocytic Lymphohistiocytosis: Clinical Presentations and Diagnosis. *J Allergy Clin Immunol Pract* 2019; 7: 824–832.
66. Daver N, McClain K, Allen CE, et al. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. *Cancer* 2017; 123: 3229–3240.
67. Zandvakili I, Conboy CB, Ayed AO, et al. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience. *Am J Hematol* 2018; doi: 10.1002/ajh.25063.
68. Cuglievan B, Miranda RN. Kikuchi-Fujimoto disease. *Blood* 2017; 129: 917–918.